Stockwinners Market Radar for August 31, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:46 EDT United Therapeutics 'pleased' with court decision in patent litigation - United Therapeutics Corporation (UTHR) announced that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics' U.S. patents 9,593,066 and 10,716,793. This litigation concerns whether Liquidia Technologies, Inc.'s (LQDA) proposed treprostinil inhalation powder, Yutrepia, would infringe the '066 and '793 patents. The Court determined that Liquidia would induce infringement of various claims of the '793 patent by marketing Yutrepia. The '793 patent relates to a method of administering treprostinil via inhalation. The Court also concluded that Liquidia failed to prove that any claim of the '793 patent at issue is invalid. As a result of the Court's decision, United Therapeutics expects the Court to enter an injunction barring the U.S. Food and Drug Administration from granting final approval for Yutrepia until expiration of the '793 patent, May 14, 2027, as required by 35 U.S.C. Section 271(e)(4)(A). The Court also determined that Yutrepia would infringe several claims of the '066 patent, but found those claims to be invalid. The '066 patent relates to a method of making treprostinil, the active pharmaceutical ingredient in both Tyvaso Inhalation Solution and Tyvaso DPI Inhalation Powder. Both parties have the right to appeal. United Therapeutics is evaluating the Court's opinion and next steps, including the potential for appealing the Court's decisions on the '066 patent. "We're pleased with the Court's decision on the '793 patent, and our legal team is evaluating options for the '066 patent," said Shaun Snader, Vice President and Associate General Counsel - IP and Litigation at United Therapeutics. "Today's decision vindicates our claims that Yutrepia is an infringing product, and we will continue to vigorously defend our intellectual property."

18:39 EDT California Independent System Operator issues Flex Alert for power conservation - The California Independent System Operator, or ISO, has issued a statewide Flex Alert, a call for voluntary electricity conservation, for today, Aug. 31 from 4 p.m. to 9 p.m., due to high temperatures pushing up energy demand and tightening available power supplies. With excessive heat in the forecast across much of the state and Western U.S., the grid operator is expecting high electricity demand, primarily from air conditioning use, and is calling for voluntary conservation steps to help balance supply and demand. Additional Flex Alerts are also possible through the Labor Day weekend as recordsetting temperatures are forecast across much of the West.Reference Link

18:04 EDT Woodward director buys $495K in common stock - In a regulatory filing, Woodward disclosed that its director Paul Donovan bought 5.3K shares of common stock on August 30 in a total transaction size of $495K.

17:58 EDT SNDL enters into bid agreement to acquire Superette assets - SNDL announced that, in the context of the initial order obtained by Superette Inc., Superette Ontario Inc. and certain of its subsidiaries from the Ontario Superior Court of Justice on August 30, 2022 pursuant to the Companies' Creditors Arrangement Act, it has entered into an agreement of purchase and sale with Superette, pursuant to which it proposes to acquire substantially all of the business and assets of Superette through a hybrid asset purchase and 'reverse vesting' transaction. Superette intends to return to Court on September 9, 2022 to seek approval of, among other things, an amended and restated initial order and an order approving a sale and investment solicitation process. Subject to Court approval at the comeback hearing, the Stalking Horse Agreement will serve as the "stalking horse bid" in the SISP, and is to be supervised by the Court and conducted by PricewaterhouseCoopers Inc., the Court-appointed Monitor of Superette. The Stalking Horse Bid will set the floor, or minimum acceptable bid for potential alternative bids to be submitted in the SISP, which is designed to achieve the highest and best offer for Superette's business and assets.

17:42 EDT Nvidia informed of new license requirement for China and Russia export by U.S. - In a regulatory filing, the company states: "On August 26, 2022, the U.S. government, or USG, informed NVIDIA Corporation, or the Company, that the USG has imposed a new license requirement, effective immediately, for any future export to China (including Hong Kong) and Russia of the Company's A100 and forthcoming H100 integrated circuits. DGX or any other systems which incorporate A100 or H100 integrated circuits and the A100X are also covered by the new license requirement. The license requirement also includes any future NVIDIA integrated circuit achieving both peak performance and chip-to-chip I/O performance equal to or greater than thresholds that are roughly equivalent to the A100, as well as any system that includes those circuits. A license is required to export technology to support or develop covered products. The USG indicated that the new license requirement will address the risk that the covered products may be used in, or diverted to, a 'military end use' or 'military end user' in China and Russia. The Company does not sell products to customers in Russia. The new license requirement may impact the Company's ability to complete its development of H100 in a timely manner or support existing customers of A100 and may require the Company to transition certain operations out of China. The Company is engaged with the USG and is seeking exemptions for the Company's internal development and support activities. In addition, the Company is engaging with customers in China and is seeking to satisfy their planned or future purchases of the Company's Data Center products with products not subject to the new license requirement. To the extent that a customer requires products covered by the new license requirement, the Company may seek a license for the customer but has no assurance that the USG will grant any exemptions or licenses for any customer, or that the USG will act on them in a timely manner. The Company's outlook for its third fiscal quarter provided on August 24, 2022 included approximately $400M in potential sales to China which may be subject to the new license requirement if customers do not want to purchase the Company's alternative product offerings or if the USG does not grant licenses in a timely manner or denies licenses to significant customers."

17:37 EDT Ackrell SPAC Partners I and North Atlantic Imports end combination pact - Ackrell SPAC Partners announced that, on August 27, the Company received a notice from North Atlantic Imports, purporting to unilaterally terminate the Business Combination Agreement dated as of December 22, 2021 by and between the Company, NAI, Ackrell Merger Sub , Roger Dahle, and North Atlantic Imports. As previously reported in the Company's Current Report on Form 8-K filed on August 25 NAI had declined to loan the Company the $200,000 requested pursuant to the Company's promissory note dated June 21 issued to NAI, in the principal amount of up to $600,000 . Prior to the close of business today, August 31, the Company had not received under the NAI Promissory Note, nor secured from any other party, the $200,000 required to be deposited by today into the trust account by the Company's Amended and Restated Certificate of Incorporation, as amended to extend the date by which it must consummate an initial business combination to beyond August 23.

17:27 EDT ServiceNow CFO sells $1.87M in common stock - In a regulatory filing, ServiceNow disclosed that its CFO Gina Mastantuono sold 4.3K shares of common stock on August 29th in a total transaction size of $1.87M.

17:19 EDT Dover announces $500M accelerated share repurchase program - On August 31, Dover established an accelerated share repurchase program with Bank of America to repurchase $500M of its common stock, par value $1.00 per share. The company is conducting the accelerated share repurchase under a repurchase authorization for an aggregate of 20,000,000 shares approved by its board of directors in November 2020. Approximately [] shares of common stock repurchased under the ASR will be received by the company on September 1, representing a substantial majority of the shares expected to be retired over the course of the ASR. The company intends to fund the accelerated share repurchases with commercial paper.

17:07 EDT Canfor reduces operations in Sweden - Canfor Corporation announced it reduced operating schedules effective September 12, 2022 at its Swedish facilities due to a decrease in market demand. The reduced operating schedules will result in a 15% decrease in production capacity and are anticipated to be in effect through the fourth quarter. "Rising inflation and mortgage rates in Europe, which are expected to persist into the fall, is impacting demand for lumber and as a result we are reducing production capacity. We are committed to continuing to meet the needs of our customers," said Don Kayne, President and CEO, Canfor. The decrease in production capacity will be achieved through reduced shifts. The Company will continue to assess and make adjustments to operating schedules based on changes in market demand.

17:06 EDT MongoDB drops 8% to $297 after reporting Q2 results, FY23 guidance

17:02 EDT Washington Federal names Kelli Holz CFO - Washington Federal, parent company of Washington Federal Bank, announced the promotion of Kelli Holz, veteran banker and current Senior Vice President Chief Risk Officer to Chief Financial Officer effective January 1, 2023. She replaces Vincent Beatty, who announced in January 2022 that he will be retiring at the end of this December. Kelli is both a certified public accountant and certified anti-money laundering specialist and brings 34 years of finance and risk experience in various leadership positions to this role. She was controller and interim Chief Financial Officer at Horizon Bank in Bellingham, Washington prior to that institution being acquired by Washington Federal Bank in 2010. Kelli holds an accounting and business administration degree from Western Washington University. She is also active as a member of the Board of Trustees and Treasurer for the Meridian Public School Foundation where she oversees the granting of college scholarships for high school graduates.

16:55 EDT CynergisTek stockholders vote to approve merger pact with Clearwater Compliance - CynergisTek announced that its stockholders have voted to approve the previously announced merger agreement dated May 23 with Clearwater Compliance , a healthcare focused cybersecurity, compliance, and risk management solutions firm, and approval of the proposed merger contemplated by the Merger Agreement in an all cash transaction that values CynergisTek at approximately $17.7M. CynergisTek today held its virtual special meeting of stockholders to vote on, among other things, the Merger Agreement and proposed Merger with a subsidiary of Clearwater. The first proposal, to adopt the Merger Agreement and approve the Merger, was approved by the affirmative vote of a majority of the outstanding shares of CynergisTek common stock entitled to vote thereon. The second proposal, which was a non-binding, advisory proposal to approve compensation that will or may become payable by CynergisTek to its named executive officers in connection with the Merger, was approved by the affirmative vote of the holders of a majority of the shares of CynergisTek common stock entitled to vote thereon and virtually present in person by remote communication, or represented by proxy. Under the terms of the Merger Agreement, Clearwater will acquire all of CynergisTek's common stock for $1.25 per share in cash. The parties expect the transaction to close on September 1. Upon completion of the transaction, CynergisTek's shares will no longer trade on the NYSE American Stock Market, and CynergisTek will become a private company. Full results of the vote will be reported on a Form 8-K that CynergisTek will file with the U.S. Securities and Exchange Commission. References herein to terms of the Merger Agreement are subject to, and are qualified by reference to, the full terms of the Merger Agreement, which CynergisTek filed with the SEC on Form 8-K on May 23.

16:50 EDT AnaptysBio down 16% at $19.50 upon resumption of trade

16:45 EDT South Plains Financial director Valles acquires 25,000 common shares - In a regulatory filing, South Plains Financial director Noe Valles disclosed the purchase of 25,000 common shares of the company on August 29 at a price of $26.57 per share.

16:38 EDT Granite named sole California distributer of EZ Street Asphalt - Granite announced that it is now the sole California distributer of EZ Street Asphalt, a cold asphalt. EZ Street represents the next generation of innovation in ambient asphalt technology and has the potential to reduce carbon emissions. Granite also distributes EZ Street in Arizona, Nevada and Utah. EZ Street is a polymer modified cold asphalt guaranteed to permanently repair potholes, utility cuts, overlays and edge repairs in asphalt or concrete. This addition to Granite's product line will also assist the company in meeting sustainability goals. For example, EZ Street's new "bioblends" mixture uses green fuel substitutes in place of fossil fuels and incorporates other recycled materials. Therefore, distributing this new mix will help Granite meet its environmental goals while helping clients meet their own sustainability and carbon targets one pothole at a time.

16:36 EDT AnaptysBio announces HARP trial did not demonstrate efficacy over placebo - AnaptysBio announced top-line data from its HARP Phase 2 trial for the treatment of moderate-to-severe hidradenitis suppurativa, or HS. The trial indicated imsidolimab was safe and well tolerated, however did not demonstrate efficacy over placebo in the trial's primary endpoint and key secondary endpoints. Clinical development of imsidolimab is being discontinued in hidradenitis suppurativa. Imsidolimab previously demonstrated efficacy and safety in the GALLOP Phase 2 trial in generalized pustular psoriasis, or GPP, a systemic, life-threatening inflammatory disease in which imsidolimab has been granted Orphan Disease Designation. Enrollment of the GEMINI-1 GPP Phase 3 registrational trial is ongoing and top-line data is anticipated in Q4 2023. The company plans to outlicense investigational imsidolimab prior to potential FDA approval for the treatment of GPP. AnaptysBio also continues to advance the development of two wholly-owned immune cell modulators targeting PD-1 and BTLA for autoimmune and inflammatory disease. Top-line data from the AZURE Phase 2 trial of rosnilimab, a PD-1 agonist antibody, in moderate-to-severe alopecia areata is anticipated in the first quarter of 2023, and the company expects to file a U.S. IND for an initial Phase 2 trial of ANB032, a BTLA agonist antibody, in the fourth quarter of 2022. This double-blind, placebo-controlled Phase 2 trial enrolled 149 patients, at sites located within North America and Europe, with moderate to severe hidradenitis suppurativa. Key inclusion criteria included age between 18 and 75 years, clinically confirmed ongoing moderate-to-severe HS with at least 5 inflammatory nodule and abscess (AN) lesion count, less than 20 draining fistulas and at least Hurley stage 2. Patients received subcutaneous monthly doses of imsidolimab 400 mg/200mg, imsidolimab 200 mg/100mg, or placebo in a 16-week treatment double-blind placebo-controlled period followed by a 16-week extension period. Placebo patients were re-randomized in a 1:1 ratio to imsidolimab 400 mg/200 mg or imsidolimab 200 mg/100 mg in the extension period. Mean baseline total inflammatory nodule and abscess lesion count for the imsidolimab high dose arm, the imsidolimab low dose arm and placebo arm were 14.0, 11.9 and 12.1, respectively. Mean baseline draining fistula count for high dose arm, low dose arm and placebo arms were 4.1, 2.7 and 3.1, respectively. Imsidolimab was safe and well tolerated with no imsidolimab-related serious or severe adverse events reported. The majority of treatment-emergent adverse events, or TEAEs, except for COVID-19, were related to underlying HS, were mild to moderate in both imsidolimab arms and resolved without leading to treatment discontinuation and number of TEAEs or TEAE timing did not correlate with dosing. The most common TEAEs observed across imsidolimab and placebo dosed patients were COVID-19 and Hidradenitis, which were deemed unrelated to treatment. Serious TEAEs were observed in 6.1% of placebo patients vs. 4.0 % on imsidolimab low dose and 0 in the imsidolimab high dose. Two cases were COVID-19 that occurred in the imsidolimab low dose arm, and all other Serious TEAEs occurred in placebo arm, including right ring finger abscess, abortion spontaneous, and worsening HS. The primary endpoint was mean change in AN lesion count from baseline at week 16. A secondary endpoint, the Hidradenitis Suppurativa Clinical Response (HiSCR) measure, was also assessed to measure improvement in HS. HiSCR50 is defined as at least 50 percent reduction from baseline AN lesion count and no increase for either abscess or draining fistula count at 16 weeks. HiSCR50 is the endpoint that has been utilized to date for evaluation of HS by regulatory agencies.

16:32 EDT Booking Holdings chairman Mylod acquires 500 common shares - In a regulatory filing, Booking Holdings chairman Robert Mylod, Jr. disclosed the purchase of 500 common shares of the company on August 29 at a price of $1,912.365 per share.

16:25 EDT AnaptysBio to resume trading at 16:45ET

16:24 EDT Costco reports August sales of $17.55B, up 11.4% - Reports August comparable sales up 8.7%.

16:18 EDT Molina Healthcare wins Iowa Medicaid contract - Molina Healthcare confirmed that the Iowa Department of Health and Human Services has announced its intent to award Molina's Iowa health plan a Medicaid managed care contract pursuant to the Request for Proposal issued by HHS on February 17, 2022. The new contract for Molina's Iowa health plan is expected to begin on July 1, 2023, with a contract duration of four years with a possible additional four years. Molina's Iowa health plan will be one of three managed care organizations offering health care coverage to approximately 850,000 total Medicaid beneficiaries in the state. "We are honored that HHS has selected Molina to help serve Iowa's citizens," the Company said in a statement. "Molina's mission is to improve the health and lives of our members by delivering high-quality health care, and we look forward to fulfilling that mission in Iowa."

16:15 EDT Scotts Miracle-Gro CFO Cory Miller departs, David Evans named interim CFO - Scotts Miracle-Gro announced that David Evans has been named chief financial officer on an interim basis replacing Cory Miller, who has departed the company. The company has engaged a leading executive search firm to assist in identifying a permanent CFO with a focus on external candidates.

16:13 EDT Pure Storage jumps 7% to $31.05 after Q2 results, FY23 guidance top estimates

16:10 EDT AnaptysBio trading halted, news pending

16:01 EDT MorphoSys chief R&D officer Malte Peters to retire - MorphoSys announced that Malte Peters, M.D., the company's Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022. His successor will be Tim Demuth, M.D., Ph.D., current Chief Medical Officer of Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company. Tim will start his new role on October 1. He will report to MorphoSys' CEO, Jean-Paul Kress, M.D., and be a member of the company's Executive Committee. At this time, Malte will step down from his operational responsibilities. "On behalf of the entire Supervisory Board, I want to thank Malte for the remarkable contributions he has made to science, modern medicine and human health over the course of his distinguished career," said Marc Cluzel, M.D., Ph.D., Chairman of the Supervisory Board of MorphoSys. "We are grateful for the strong pipeline and team Malte has built at MorphoSys. We wish him all the best as he begins this new chapter, and we look forward to working with Tim."

15:18 EDT Montauk Renewables to construct second RNG processing facility in Ohio - Montauk Renewables announced the planned construction of a second renewable natural gas, or RNG, processing facility at its Apex landfill gas project in Amsterdam, Ohio. The planned project is being driven by projections in biogas feedstock availability from the host landfill over the next 12 to 18 months. The company is targeting an approximate 40% increase in RNG processing capacity with the addition of the second facility. It is expected to add up to 2,100 MMBtu per day production capacity and expand the infrastructure for the conversion of LFG to RNG. The project is expected to be completed in 2024, based on currently forecasted biogas feedstock volumes that are anticipated to be available from the host landfill at the time of commissioning. The company currently expects the capital investment to range between $25M-$30M in total project costs over the next 12 to 18 months, beginning in the fourth quarter of 2022.

14:49 EDT MicroStrategy falls after AG sues company for helping CEO evade taxes - Shares of MicroStrategy (MSTR) are down $16.32, or 7%, to $223.91 in Wednesday afternoon trading after Washington D.C. Attorney General Karl Racine announced a lawsuit against Michael Saylor, who he calls "a billionaire tech executive who has lived in the District for more than a decade but has never paid any DC income taxes," for tax fraud. The office is also suing his company, MicroStrategy, for "conspiring to help him evade taxes he legally owes on hundreds of millions of dollars he's earned while living in DC," said the Attorney General, who noted this as the first lawsuit brought under the district's recently amended False Claims Act encouraging whistleblowers to report residents who evade tax laws by misrepresenting their residence. In the lawsuit filing, which seeks a jury trial, the District of Columbia, through its Office of the Attorney General, claims that Saylor "knowingly avoided income taxes he owed to the District by fraudulently claiming to be a resident of other, lower-tax jurisdictions while maintaining his domicile and place of abode in the District, including living in a luxury penthouse on the Georgetown waterfront and docking multiple yachts on the District's Potomac riverfront from 2005 to present." In addition, the suit claims that "on information and belief, from 2005 to the present, Saylor has avoided more than $25 million in District taxes owed." Also, the suit claims defendant MicroStrategy "knew that Saylor was in fact a District resident, but instead of accurately reporting his address to local and federal tax authorities and correctly withholding District taxes, the company conspired with Defendant Saylor to facilitate his tax avoidance scheme." Saylor, who previously served as MicroStrategy's Chairman and Chief Executive Officer, assumed the new role of Executive Chairman as of August 8.

14:43 EDT McEwen Mining trading resumes

14:37 EDT Liquidia Technologies trading resumes

14:33 EDT MEGL Stock trading halted, volatility trading pause

14:26 EDT Liquidia Technologies trading halted, volatility trading pause

14:20 EDT McEwen Mining trading halted, news pending

14:04 EDT Iowa HHS to award new managed care contracts to Amerigroup, Molina - The Iowa Department of Health and Human Services, or HHS, announced the intent to award contracts to Amerigroup Iowa and Molina Healthcare of Iowa. "Iowa Total Care will also continue to serve Iowans in the Iowa Medicaid program. Iowa Medicaid will work closely with Molina as they stand up their operations in Iowa and we will communicate with members and providers as this new option for health coverage becomes available," the HHS stated. "For more than a year, Iowa Medicaid has worked to update the scope of the managed care program to reflect the priorities of improved outcomes, member-centric care, and cross-system coordination more accurately. This announcement of the intent to award and the selection of these MCOs, alongside Iowa Total Care, will effectuate these changes. This announcement continues the State's work with Amerigroup and this third MCO will enhance choice for members and incent innovation in the Iowa Medicaid program," the HHS added. Reference Link

13:49 EDT D.C. AG also suing MicroStrategy for conspiring with Michael Saylor - Washington D.C. Attorney General Karl Racine said via Twitter, "NEW: Today, we're suing Michael Saylor - a billionaire tech executive who has lived in the District for more than a decade but has never paid any DC income taxes - for tax fraud. We're also suing his company, MicroStrategy, for conspiring to help him evade taxes he legally owes on hundreds of millions of dollars he's earned while living in DC. It's the 1st lawsuit brought under DC's recently amended False Claims Act encouraging whistleblowers to report residents who evade our tax laws by misrepresenting their residence. Led by @ChmnMendelson, @councilofdc unanimously updated the law & gave us enforcement authority."

13:45 EDT MicroStrategy drops 2% after D.C. AG announces suit against Michael Saylor

13:32 EDT North American rail traffic up 1.5% for the week ending August 27 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending August 27. For this week, total U.S. weekly rail traffic was 511,574 carloads and intermodal units, up 1.4% compared with the same week last year.Total carloads for the week ending August 27 were 242,633 carloads, up 3.4% compared with the same week in 2021, while U.S. weekly intermodal volume was 268,941 containers and trailers, down 0.3% compared to 2021. North American rail volume for the week ending August 27 , on 12 reporting U.S., Canadian and Mexican railroads totaled 340,747 carloads, up 2.4% compared with the same week last year, and 359,832 intermodal units, up 0.7% compared with last year. Total combined weekly rail traffic in North America was 700,579 carloads and intermodal units, up 1.5%. North American rail volume for the first 34 weeks of 2022 was 22,997,308 carloads and intermodal units, down 2.7% compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:28 EDT FDA approves Genzyme's Xenpozyme to treat ASMD - The U.S. Food and Drug Administration approved Xenpozyme for intravenous infusion in pediatric and adult patients with Acid Sphingomyelinase Deficiency, or ASMD, a rare genetic disease that causes premature death. "Xenpozyme is the first approved medication to treat symptoms that are not related to the central nervous system in patients with ASMD," the FDA stated. The FDA granted the approval of Xenpozyme to Genzyme, a fully owned subsidiary of Sanofi. Reference Link

12:46 EDT ShiftPixy says new 1:100 reversed shares begin trading on Nasdaq on September 1 - ShiftPixy announced that at the close of business today in Wyoming, pursuant to the vote of its shareholders on July 19 to effect a one-for-one hundred reverse split of the company's issued and outstanding shares of common stock, the split will become effective as filed with the Secretary of State of Wyoming. The new reversed shares will begin trading on Nasdaq on September 1, the start of the company's new fiscal year.

12:04 EDT MGM reports public tender offer for LeoVegas shares accepted by 96% of holders - MGM Resorts International announced that its public tender offer for the shares of LeoVegas AB has been accepted by 96% of LeoVegas shareholders at a price of SEK 61.00 in cash per share, equivalent to a total tender value of approximately $604M. Settlement of the shares is expected to be initiated on or around September 7. "The completion of this transaction represents a major milestone for MGM Resorts as we continue to pursue our strategy of growing our online gaming footprint worldwide," said MGM Resorts' CEO and President Bill Hornbuckle. "We look forward to welcoming the LeoVegas team and are excited to begin working with them to grow our global digital gaming business and maximize the full potential of our omnichannel strategy."

12:00 EDT Blue Apron falls -9.4% - Blue Apron is down -9.4%, or -56c to $5.46.

12:00 EDT Weber falls -14.2% - Weber is down -14.2%, or -$1.17 to $7.04.

12:00 EDT ChargePoint rises 12.6% - ChargePoint is up 12.6%, or $1.83 to $16.32.

11:49 EDT Tencent, Sony acquire minority stakes in 'Elden Ring' developer FromSoftware - Kadokawa Corporation announced that subsidiary FromSoftware, a game developer known for "Elden Ring" and "Dark Souls," resolved in its meeting of the board of directors on August 31, 2022 to issue new shares of its stock to Sixjoy Hong Kong Limited, a subsidiary of Tencent Holdings Limited (TCEHY), and Sony Interactive Entertainment, a subsidiary of Sony (SONY), of a third-party allotment. There will be no change in the scope of consolidation of the Kadokawa Group resulting from the Third-Party Allotment. Sixjoy acquired 16.25% of FromSoftware's shares, while SIE acquired 14.09% of shares. Kadokawa remains the largest stakeholder in the game studio, holding 69.66% of the shares. Kadokawa believes that the Third-Party Allotment will contribute to the medium- to long-term improvement of the Group's corporate value, while the impact of the Third-Party Allotment on the company's consolidated financial results for the fiscal year ending March 31, 2023 is expected, at the time of this report, to be minor. The Fly notes that "Elden Ring," which released this year to rave reviews and high sales numbers, was published by Bandai Namco (NCBDY). Reference Link

10:46 EDT BAE Systems appoints Guy Montminy as SVP, finance - BAE Systems has named Guy Montminy as its senior vice president for finance, effective Sept. 5, 2022. In his role, Montminy will be responsible for the financial operations of the company's U.S.-based businesses, which employ more than 34,000 employees in the United States, United Kingdom, and Sweden, and generated 2021 sales of nearly $12.5B. Montminy will report to BAE Systems, president and CEO Tom Arseneault, and serve as a member of the Inc. senior leadership team. This is a role he held previously, from 2014 to 2016. Montminy returns from his current role where he served as an advisor on a wide range of company initiatives. Montminy succeeds Scott Howat, who has served as senior vice president for finance since 2016. Howat is leaving the company to spend more time with his family, and pursue his outside passions.

10:32 EDT Vizio announces addition of four free channels from E.W. Scripps to WatchFree+ - Vizio (VZIO) announced it has added four additional free channels from The E.W. Scripps Company (SSP), including ION, ION Mystery, Bounce XL and Grit Xtra, on Vizio's free streaming service, WatchFree+. "We are pleased to be working with Scripps to expand their content offering on Vizio, helping us deliver on our commitment to provide endless entertainment options and enhanced consumer experiences. Thanks to these popular Scripps channels with some all-time consumer favorite shows, we can offer an ever-wider variety of free programming across genres and interests and bring more options to millions of WatchFree+ viewers," said Katherine Pond, Group Vice President, Platform Content and Partnerships at Vizio.

10:26 EDT TeraWulf announces amendments to Nautilus JV agreement - TeraWulf announced that the Company and a subsidiary of Talen Energy Corporation have reached an agreement to amend their existing joint venture agreement for the Nautilus Cryptomine bitcoin mining facility, which is located adjacent to, and will source zero-carbon nuclear power directly from, Talen's 2.5 GW Susquehanna Station in Pennsylvania. The Nautilus Cryptomine Facility benefits from one of the lowest electricity costs among publicly traded bitcoin mining peers in the United States with contracted power for the first 100 MW of gross mining capacity at $0.02 per kilowatt hour for an initial term of five years. Under the amendments, TeraWulf will maintain the benefit of its previous share of 50 MW of the Initial Block at $0.02 per kilowatt hour. TeraWulf's affiliate, Beowulf Electricity & Data Inc., will continue to operate the Nautilus Cryptomine facility pursuant to its previously announced facility services agreement. Under the amended agreement, TeraWulf will retain a thirty-three percent ownership interest in the Nautilus JV. The Nautilus Cryptomine Facility has access to up to 300 MW of mining capacity from the Susquehanna Station, with each of the JV members having the right to increase digital infrastructure capacity at the site by 50 MW beyond the initial 200 MW planned. The Nautilus Cryptomine Facility is expected to be the first bitcoin mining facility site powered by 100% "behind the meter" zero-carbon nuclear energy. The Nautilus Cryptomine Facility remains on track to commence mining operations in Q4 2022. Simultaneously with the amendments to the Nautilus JV, TeraWulf has reached a commercial understanding with Bitmain Technologies whereby TeraWulf's previous payments are expected to be utilized for future antminer shipments comprised of Bitmain S19 XP and S19j Pro miners. The Company currently anticipates minimal additional cash payments to complete its miner purchases for existing miner orders. This arrangement is expected to provide TeraWulf the flexibility to align the timing and delivery of miners with the infrastructure deployment at TeraWulf's two facilities.

10:16 EDT Pfizer, BioNTech confirm FDA authorization of omicron bivalent vaccine - Pfizer (PFE) and BioNTech (BNTX) announced that the Food and Drug Administration granted Emergency Use Authorization of a 30-microgram booster dose of the Pfizer-BioNTech COVID-19 vaccine, bivalent, for individuals ages 12 years and older. An application for an omicron-adapted bivalent vaccine for children 5 through 11 years of age is planned for submission to the FDA in early October, the companies said. They added that they are working with the FDA to prepare an application for an omicron-adapted bivalent vaccine in children 6 months through 4 years of age. "The authorization of the bivalent COVID-19 vaccine is based on clinical data from Pfizer and BioNTech's Omicron BA.1-adapted bivalent vaccine as well as pre-clinical and manufacturing data from their Omicron BA.4/BA.5-adapted bivalent vaccine," the companies said. They will supply the original and bivalent vaccines under their existing supply agreement with the U.S. government. Pfizer and BioNTech have submitted data on their omicron-adapted bivalent vaccines to the European Medicines Agency and other regulatory authorities around the world. The original Pfizer-BioNTech COVID-19 vaccine will remain available as a booster dose for children 5 through 11 years of age and as a primary series for those 6 months of age and older.

10:06 EDT Airspan Networks announces two customer orders worth over $20M - Airspan Networks says it has recently received two customer orders for its new products for Fixed Wireless Access and 5G. The company received its first order in excess of $10M for the new A6/B6x FWA broadband access and backhaul platform. Separately, with another customer, Airspan has received additional orders in excess of $10M for an ongoing Open RAN network build in Asia, including expansion of the Ruggedized Distributed Unit deployment for 4G network operation and a new product, a 5G antenna element that will work in a multi-vendor environment to improve macro radio performance. Eric Stonestrom, Chairman and CEO comments: "It is exciting to be part of this major national 5G build which extends 5G mobile and fixed services to millions of people. Our innovation with this product line continues to win us positions in the world's most exciting network expansions."

10:00 EDT Web Street, Inc. falls -6.5% - Web Street, Inc. is down -6.5%, or -$2.20 to $31.75.

10:00 EDT Forge Global falls -7.2% - Forge Global is down -7.2%, or -30c to $3.87.

10:00 EDT FiscalNote rises 9.7% - FiscalNote is up 9.7%, or 72c to $8.18.

10:00 EDT Bausch Health rises 13.6% - Bausch Health is up 13.6%, or 69c to $5.81.

09:55 EDT JZ Stock trading resumes

09:49 EDT Alfa Laval acquires Scanjet - Alfa Laval has acquired Scanjet, a global supplier of tank cleaning equipment and solutions for marine, offshore and industrial applications. The company said, "The acquisition will extend Alfa Laval's broad tanker offering, creating a more comprehensive product portfolio for cargo tanks Scanjet's intelligent tank management solutions will be a valuable complement to Alfa Laval's sustainable marine offering as they reduce the water usage and energy consumption connected with tank cleaning. Adding Scanjet to Alfa Laval's portfolio will support customer efficiency at every stage of cargo handling." Scanjet employs about 150 people and has global presence with factories in Sweden, Poland and Indonesia, and a turnover of about SEK 300M.

09:47 EDT Forge Global falls -6.5% - Forge Global is down -6.5%, or -27c to $3.90.

09:47 EDT Pinterest rises 7.2% - Pinterest is up 7.2%, or $1.58 to $23.54.

09:47 EDT Snap rises 8.5% - Snap is up 8.5%, or 85c to $10.87.

09:37 EDT Airspan Networks trading halted, news pending

09:33 EDT WidePoint launches Intelligent Technology Management Solution - WidePoint announced the launch of the new ITMS, Intelligent Technology Management Solution. ITMS provides a customizable solution for managing, tracking, analyzing and securing technology assets. Users can login, see real time delivery status, complete secure device acceptance, digitally sign IT asset confirmation receipts, and then initiate secure device return and data sanitization at the end of use. Leadership can account for every device every step of the way, from deployment to retirement, cradle to grave.

09:27 EDT Snap says 'reprioritizing investments' to focus on three strategic priorities - In an investor slide presentation, Snap said: We will substantially reduce or eliminate investments not directly connected to our three strategic priorities: Snap Originals - Going forward, we will focus our efforts on content created by our partners and by creators; Minis and Games - We will shift Minis and Games into maintenance mode with substantially reduced investment; Hardware - We're narrowing our investment scope in Spectacles to focus on highly differentiated long-term research and development efforts. We will discontinue further development on our flying camera, Pixy; Zenly, Voisey - We intend to wind down these standalone apps and focus on Snap Map and Sounds within Snapchat."

09:25 EDT Snap says $500M share repurchase program now complete - Snap said it intends to continue to pay its team members "competitively and leverage stock-based compensation to drive an ownership oriented culture. Its $500M share repurchase program is now complete with 3.1% of outstanding shares repurchased at an average price of $9.75. Snap added that its initial stock repurchase program more than fully offset all stock-based compensation related dilution from the trailing 12 months.

09:20 EDT Snap announces 20% reduction of full time employees - Snap announced a plan to reduce its global headcount by approximately 20% of full time employees. "The headcount reduction is part of a broader strategic reprioritization by the company to focus on our top priorities, improve cost efficiencies, and drive toward profitability and positive free cash flow," Snap said in a regulatory filing. As a result of the strategic reprioritization, Snap currently estimates that it will incur pre-tax charges in the range of $110M to $175M, primarily consisting of severance and related costs, contract termination costs, and other impairment charges, of which $95M to $135M are expected to be future cash expenditures. The majority of these costs are expected to be incurred during Q3. "Potential position eliminations in each country are subject to local law and consultation requirements, which may extend this process into the fourth quarter of 2022 or beyond in certain countries," it added.

09:16 EDT Blink Charging elects Cedric Richmond to board of directors - Blink Charging announced the election of former senior advisor to President Biden and former Congressman, Cedric Richmond, to the Blink Board of Directors by the board on August 25, 2022. Richmond will serve on the Board's environmental, social and governance committee.

09:13 EDT Lexaria Bioscience receives new patent in Mexico - Lexaria Bioscience announced its receipt of its 27th worldwide patent granted in Mexico under registration #390001. This patent is from Lexaria's third patent family, "Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents" from which patents have already been issued in Australia, India and Japan. The patent is applicable to a range of active ingredients that includes but is not limited to non-psychoactive cannabinoids and NSAIDs. Types of products covered include certain pharmaceutical product formats as well as a wide variety of ready-to-drink consumer retail beverage products. Additional claims granted in Mexican patent #390001 include the treatment of neurological diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia, and Human Immunodeficiency Virus dementia; obesity; metabolic disorders such as insulin related deficiencies and lipid profiles, hepatic diseases, diabetes, and appetite disorders; cancer chemotherapy; benign prostatic hypertrophy; irritable bowel syndrome; biliary diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine, or cocaine addiction.

09:10 EDT Lexaria Bioscience receives patent in Mexico - Lexaria Bioscience announced its continued accumulation of international patent recognition with the receipt of its 27th worldwide patent granted in Mexico under registration #390001. This patent is from Lexaria's third patent family, "Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents" from which patents have already been issued in Australia, India and Japan. The patent is applicable to a range of active ingredients that includes but is not limited to non-psychoactive cannabinoids and NSAIDs. Types of products covered include certain pharmaceutical product formats as well as a wide variety of ready-to-drink consumer retail beverage products. Given Lexaria's continued pursuit of regulatory approval of DehydraTECH-CBD for the treatment of hypertension in regulated pharmaceutical applications, certain claims allowed in this new Mexican patent to use DehydraTECH-processed non-psychoactive cannabinoids to treat cardiac and cardiometabolic disorders are of particular value to the Company. Additional claims granted in Mexican patent #390001 include the treatment of neurological diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia, and Human Immunodeficiency Virus dementia; obesity; metabolic disorders such as insulin related deficiencies and lipid profiles, hepatic diseases, diabetes, and appetite disorders; cancer chemotherapy; benign prostatic hypertrophy; irritable bowel syndrome; biliary diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine, or cocaine addiction.

09:07 EDT Enthusiast Gaming, NFL partner to launch NFL Tuesday Night Gaming - the National Football League, NFL, and Enthusiast Gaming Holdings announced a gaming collaboration bringing together NFL players and Legends and gaming content creators from marquee gaming organizations including Luminosity Gaming. This multi-year partnership will see the launch of NFL Tuesday Night Gaming, where teams will compete head-to-head across popular video game titles. NFL Tuesday Night Gaming will debut September 13 at 6:30 PM ET, and stream live on YouTube in the United States and Canada on Tuesdays during the 2022-2023 NFL regular season. Fans can expect to see a rotating roster of 12 NFL players or Legends and 6 gaming creators competing across three game titles each week in an new format. After each week's gameplay, teams will be ranked with the top four teams qualifying for a single-elimination playoff, where one team will be crowned champion of the inaugural NFL Tuesday Night Gaming season.

09:06 EDT Baxter gets FDA clearance of Novum IQ syringe infusion pump - Baxter International announced U.S. Food and Drug Administration 510k clearance of its new Novum IQ syringe infusion pump with Dose IQ Safety Software, representing Baxter's latest developments for infusion therapy. The Novum IQ SYR has the capability to fully integrate with hospital electronic medical records through Baxter's IQ Enterprise Connectivity Suite. "We are thrilled to bring a new syringe infusion pump to the market that represents the next generation of Baxter's intelligent infusion ecosystem," said Heather Knight, president, Medication Delivery, Acute Therapies, Clinical Nutrition, Latin America and Canada. "Together, the Novum IQ syringe infusion pump, Dose IQ Safety Software and IQ Enterprise Connectivity Suite advance the interoperability and data insights needed to help prevent harm and personalize therapy for patients, including neonates and other fragile patients."

09:05 EDT Seagate down 7% after resumption of trading - Shares of Seagate are down 7% at $64.55 upon resumption of pre-market trading following the company's Q1 guidance cut. The stock's indicated pre-market levels are at the lowest point since January of 2021, breaching the multi-month lows of $67.35 seen last month.

09:05 EDT Sprague Resources announces amendment to merger agreement with Hartree - Sprague Resources announced that it has entered into an amendment to the agreement and plan of merger with an affiliate of Hartree Partner, pursuant to which Hartree will acquire all of the outstanding common units of the Partnership not already owned by Hartree and its affiliates. The Amendment, among other things, provides for an amendment of the date prior to which the Merger may not close without Hartree's consent from July 31, 2022 to November 28, 2022, for an amendment of the date after which either party may terminate the Merger Agreement should the Merger have not closed from December 2, 2022 to March 2, 2023, in addition to the previously agreed merger consideration of $19.00 per Common Unit, that the Partnership's unitholders unaffiliated with Hartree will receive an additional $1.00 per Common Unit in cash as consideration for the amendment to the Inside Date, for the removal of the closing conditions in the Merger Agreement specific to Hartree, and that the Partnership will pay a cash distribution to its unitholders for the calendar quarter ending September 30, 2022, in an amount not less than $0.4338 per Common Unit, regardless of whether the closing of the Merger occurs prior to September 30, 2022. Following execution of the Amendment, the Partnership expects that the Merger will close in the fourth quarter of 2022.

09:03 EDT VerifyMe enters multi-year contract extension with strategic partner - VerifyMe announced that the company has entered into a new multi-year extension of their professional services agreement with its strategic partner to provide proactive customer service to their customers. The term of the agreement, originally scheduled to expire on March 1, 2024, has been extended to March 1, 2026.

09:03 EDT Hershey names Marlene Creighton as Global Chief Sales Officer - Hershey has named Marlene Creighton as Global Chief Sales Officer, effective September 5. After 26 years with Hershey, Phil Stanley, currently serving in this role, will transition out of the company to pursue his next opportunity. Creighton has spent the last four years at Hershey, after more than 20 years of CPG experience working across sales, category management and brands with P&G, Unilever and now Hershey.

09:02 EDT FaZe Holdings announces renewal of partnership with McDonald's USA - FaZe Holdings announced the renewal of its partnership with McDonald's USA. The partnership, which began last year, will continue to focus on innovative ways to connect with the next generation of gamers and will advance successful campaigns from the past year while launching new initiatives. To kick off the renewed partnership, FaZe Clan and McDonald's will have a presence at PAX West this weekend, a gaming convention in Seattle, WA. McDonald's will be hosting activities for fans at their booth, including a meet-and-greet with FaZe talent, and sponsoring a showcase that gives FaZe talent the opportunity to preview and play new and soon-to-be-released games at the convention.

09:00 EDT Seagate trading resumes

08:54 EDT Sprague Resources trading halted, news pending

08:47 EDT The Very Good Food Company postpones annual general meeting of shareholders - The Very Good Food Company announced that it is postponing its annual general meeting of shareholders which was to be held on October 11. The company's Board of Directors decided to postpone the AGM until the company has appointed a successor auditor. Following the resignation of KPMG LLP as the company's auditor effective August 16, the company's Audit Committee has been engaged in discussions with potential successor audit firms and the company expects to engage a new audit firm shortly. KPMG has confirmed there have been no "reportable events", as such term is defined in National Instrument 51-102 - Continuous Disclosure Obligations.

08:47 EDT Waitr Holdings announces new partnership with University of Alabama - ASAP, the on-demand delivery brand for Waitr Holdings, has announced a new partnership with the University of Alabama. The new agreement brings back in-stadium ordering to Bryant-Denny Stadium - along with the new addition of beer and wine as pick-up options. Fans will be able to order food and beverages right from their phones using the new ASAP app. ASAP's in-stadium ordering technology allows fans to continue watching the game and avoid long lines at concession areas. The partnership with Alabama includes ASAP branding throughout the stadium. The video board, in-stadium LED, and other signage will promote ASAP mobile ordering with the concession areas clearly identifying ASAP pick-up sites.

08:44 EDT Ensysce Biosciences debuts redesigned company website - Ensysce Biosciences announced the launch of the new Ensysce website at www.ensysce.com. The Company's updated website highlights the TAAP and MPAR technology platforms, the depth of the team, and our truly unique products for the treatment of severe pain.

08:43 EDT American Resources sells rights to carbon nanostructure, graphene patents - American Resources Corporation announced that it has sold its exclusive patent rights in carbon nanostructure and graphene technology to Novusterra for $16 million paid in all Class A common Novusterra shares. Pursuant to terms of the transaction: Dr. Gregory Jensen, PhD will be named Chief Executive Officer and Director of Novusterra and Dr. Gerardine Botte as the Chief Technical Officer; Mark LaVerghetta will be named Chairman of the Board, other board members will include: Dr. Byron Price, Eugene Nichols and Goran Antic; Novusterra will fund the sponsored research program at Texas Tech University to advance the preprocessing, carbon nanostructure and graphene technology to commercialization; Novusterra will work to list on a public exchange in an effort to fund the development and commercialization of the technology with a focus on infrastructure and battery storage applications; Novusterra will have rights to lease certain properties and facilities in Indiana, Kentucky and West Virginia from American Resources which will allow for synergistic opportunities for both companies as they work to develop a consistent and sustainable feedstock of carbon material; and Novusterra and ReElement Technologies will collaborate and enter into a joint services agreement on electrolysis technology which is utilized in both companies' processes and will therefore generate additional synergies and cost saving technologies.

08:40 EDT Seagate to resume trading at 9:00 am ET - Seagate will resume trading at 9:00 am ET, with quotation set to resume at 8:55 am ET, according to Nasdaq. Shares were halted, pending news, ahead of the company announcing that it has lowered its fiscal Q1 outlook and now expects non-GAAP EPS "meaningfully below" prior guidance of at least $1.20.

08:39 EDT Telos announces launch of latest enhancements of Xacta - Telos Corporation announced the launch of the latest enhancements of Xacta, its cyber risk management and compliance analytics platform. This release introduces new features that allow Xacta users to quantify and align cyber risk with business objectives by expressing the risks in financial terms or dollar amounts. Additionally, this new version of Xacta expands on the intelligent workflow capability that uses data to automate and advance workflow to reduce the human input required in the IT risk management process. Further, Xacta's API has been advanced and native integrations with Tenable and STIG Viewer added, enabling a more diverse integration ecosystem.

08:38 EDT Navitas Semiconductor announces New York investor meeting - Navitas Semiconductor has announced an in-person investor meeting, at Nasdaq New York, on September 13th. Navitas co-founder and CEO, Gene Sheridan, and CFO Ron Shelton will detail how gallium nitride and silicon carbide power semiconductors replace legacy silicon chips to address a $22B/year market by 2026 and enable a 6 Gton/year reduction in CO2e emissions by 2050. The recent, accretive acquisition of GeneSiC Semiconductor will be reviewed in detail, with a focus on complementary technology, company structure and Navitas' unique, 'pure-play' next-gen, system-focused go-to-market strategy. Attendees will see examples of mobile, data center, motor drive, solar and EV applications highlighting performance benefits, including energy savings, charging speed, system size and cost. This in-person event at NASDAQ's 4 Times Square location in New York from 1pm to 4pm EDT, with a formal presentation followed by live Q&A and live hardware demonstrations including ultra-fast mobile charging, data center, EV and motor drive applications.

08:37 EDT X4 Pharmaceuticals to host investor webinar on Mavorixafor Phase 1b data - X4 Pharmaceuticals announced that it will host an investor webinar to present and discuss new data from its Phase 1b trial evaluating its lead clinical candidate, mavorixafor, in patients with idiopathic, cyclic, and congenital neutropenia. The event will include perspectives from patients and clinical experts on the unmet medical need and the opportunity for innovative treatment development. Members of X4 Pharmaceuticals' management team will present clinical data on 25 patients from this fully enrolled trial and discuss mavorixafor's potential to treat broader chronic neutropenia populations beyond its lead indication in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome. A live Q&A will follow the formal presentations. Webcast Details: Date: Tuesday, September 27, 2022; Time: 8:00 - 9:00 a.m. ET.

08:36 EDT Eneti repurchases 2.29M shares of common stock for $17M - Eneti announced that it repurchased 2,292,310 shares of its common stock from INCJ, Ltd., for approximately $17M The Company had issued the Shares to INCJ, Ltd. as part of the acquisition price paid by the Company to acquire Seajacks in August 2021. The repurchase of the Shares was made under the Company's existing board authorized repurchase plan. As of August 31, 2022, $14.9M remains available under the repurchase plan.

08:33 EDT Edible Garden completes acquisition of greenhouse facility in Michigan - Edible Garden completed the acquisition of a five-acre greenhouse facility in Grand Rapids, Michigan, which will operate as Edible Garden Heartland. The new CEA facility, leveraging advanced AgTech, is expected to be fully operational by year's end, with the capacity to support up to $20 million in annualized revenue. In addition to serving customers in the Midwest, the facility will house the Company's state-of-the-art research and development center, focused on improving existing products, developing new products, innovations in plant-based protein and nutraceuticals, as well as applying advanced agricultural technologies. It will also be home to the first commercial installation of Edible Garden's proprietary hybrid vertical growing system. Mike Sudbury, General Manager at Edible Garden, will lead the Grand Rapids facility. The acquisition also includes an existing horticultural business that has historically generated approximately $2 million in annual revenue and provides the Company with the potential for a range of cross-selling opportunities. The Company is partnering with the University of Michigan's School of Environment & Sustainability and Erb Institute and will offer students the opportunity to work directly with Edible Garden's team to develop and implement initiatives at Edible Garden Heartland that address the environmental and societal impacts of the food industry, by harnessing the power of sustainable CEA farming.

08:32 EDT Sabre extends distribution agreement with Vietnam Airlines - Sabre announced an extended distribution agreement with Vietnamese flag carrier Vietnam Airlines. The new deal means that Vietnam Airlines will continue to distribute its content to the network of travel agents through Sabre's travel marketplace. In addition to Sabre's Global Distribution system, the Hanoi-based carrier also uses a comprehensive suite of SabreSonic Passenger Service System technology including reservation and ticketing, inventory and departure control solutions. Vietnam Airlines also leverages Sabre's Revenue Optimizer as well as further Sabre solutions to enable the carrier to provide travelers with a premium personalized experience.

08:32 EDT Nokia reports changes in company's own shares - A total of 5 243 560 Nokia shares held by the company were today transferred without consideration to participants of Nokia's employee share purchase plan in accordance with the rules of the plan. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plan as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 76 520 477.

08:28 EDT NextPlat invests $7M in recapitalization of Progressive Care - NextPlat announced that it has completed a strategic $7 million investment in Progressive Care. Under the recapitalization plan, NextPlat Corp, its Executive Chairman and CEO, Charles Fernandez, and board member, Rodney Barreto, and certain other investors will invest an aggregate of $8.3 million into Progressive Care. In connection with the recapitalization, NextPlat will purchase 3,000 newly issued Units of Progressive Care valued at $6 million, with each Unit comprised of one share of Progressive Care's Series B Preferred Stock and one Warrant to purchase a share of Series B Preferred Stock. In addition, NextPlat Corp, Messrs. Fernandez and Barreto, and certain other investors will purchase $2.3 million of outstanding convertible debt from an existing holder. In connection with debt purchase, NextPlat Corp and the other purchasers agreed to a fixed conversion price of $0.02 per share of common stock and removal of the blocker. NextPlat Corp and the other purchasers also agreed to reduce the interest rate on the purchased debt from 10% to 5% per annum. As part of this transaction, Mr. Fernandez will be appointed as Chairman of Progressive Care replacing Alan Jay Weisberg who will step down from his current positions to assume the new roles of Vice Chairman and CEO. Mr. Barreto will also be joining Progressive Care's board as Vice Chairman. Progressive Care intends to utilize a portion of the growth capital to further fund deployment of its digital platforms and the development and sale of new health, fitness, and beauty products.

08:27 EDT Fangdd Network announces board, management changes - Fangdd Network Group announced a few changes of the Company's board of directors, Audit Committee and management. The Board has appointed Senlin Peng as a director of the Company and a member of the Audit Committee, to succeed Ronald Cao, who has resigned from these positions for personal reasons. Jiaorong Pan has stepped down as the Company's Chief Financial Officer and assumed the role of the Chief Operating Officer of the Company, responsible for the corporate governance and execution of business strategies, plans and procedures, among other things. Shuiying Chen has been appointed as the Company's financial controller in charge of financial and accounting matters as the Company's principal financial and accounting officer. Jiancheng Li has resigned as the Company's Chief Technology Officer. Since he joined ColorLife Group in 2000, Peng has served multiple positions, including a member of the company's board of directors since 2011 and the Chief Executive Officer of the company from 2005 to 2010 in charge of overall business operations. Shuiying Chen joined FangDD in 2019. These Board, Audit Committee and management changes became effective on August 30, 2022.

08:24 EDT Aemetis comissions $10M Mitsubishi ZEBREX system at Keyes plant - Aemetis (AMTX) completed the installation and commissioning at the Keyes ethanol plant in California of the first Mitsubishi ZEBREX system in North America, reducing overall energy use and lowering the carbon intensity of ethanol. The system is now fully operational, reducing energy costs and increasing biofuel value by more than $5M per year. The cost of equipment, engineering and installation of the Mitsubishi ZEBREX system was approximately $10M. Aemetis expects to receive more than $1M of grant funding from the PG&E (PCG) and CPUC Energy Efficiency Program in support of the project. The patented ZEBREX technology replaces the energy-intensive molecular sieve ethanol dehydration process used by most fuel ethanol plants in the world. The upgrade from the traditional Pressure Swing Adsorption ethanol dehydration process to the ZEBREX system has reduced petroleum natural gas consumption at the Keyes facility by more than 20%, which is estimated to provide energy savings of approximately $3.4 million per year. Additionally, by reducing the amount of fossil fuel energy used in the production process, Aemetis expects to receive a lower carbon intensity score for the fuel ethanol produced at the Keyes plant, which will increase revenue for each gallon of fuel ethanol sold. "Implementation of the Mitsubishi ZEBREX technology at the Aemetis Keyes plant completes another significant project as we transition our ethanol production process from petroleum-based energy sources to renewable electricity," said Andy Foster, President of Aemetis Advanced Fuels Keyes. "Our engineering team worked closely with Mitsubishi in Japan to customize the design of the system for large-scale fuel ethanol production. The ZEBREX(TM) technology is delivering as promised and Mitsubishi has been an outstanding partner throughout this multi-year process," added Foster.

08:22 EDT Lifeist says CannMart reduces headcount by 30% - Reduced headcount by approximately 30%, with the majority of reductions related to personnel who were involved with the Phyto product lines. The lower headcount is expected to result in over $2 million in annualized operating expense savings at CannMart.

08:21 EDT Triumph Group awarded water tank systems contract from Diehl Aviation - Triumph Group announced that its Actuation Products and Services business has been awarded a ten year contract from Diehl Aviation to manufacture fluid flow controls. These components are used on board passenger aircraft such as the Airbus A320 and A330. Triumph has performed this work at their location in Heiligenhaus, Germany facility since 2008. Triumph Actuation Products & Services provides design, development, manufacture and support of complex electro-hydraulic and mechanical systems and equipment for the aerospace and defense industry.

08:18 EDT Olink appoints Raimond as President, Marsell as COO - Olink Holding announced several appointments in its leadership structure. Olink Chief Commercial Officer, CCO, Carl Raimond will be appointed President, effective upon the hiring of a new CCO, which is expected by the end of the year. In the interim, Raimond will continue his stewardship of the commercial organization during Raimond's second half of 2022 and lead the transition of CCO duties. In this newly created position, Raimond's role will expand from leadership of the commercial group to responsibility for corporate functions, while continuing to report to CEO Jon Heimer. In addition, Anna Marsell will become Chief Operating Officer, COO, effective December 1st, 2022. Marsell will join Olink from Galderma where she has held several leadership positions with increasing responsibility over the past ten years, including General Manager/Head of Nordic, and senior roles in decision support and strategic planning. Olink's current COO, Fredrik Netzel, will be appointed VP Operations, his role to include management of Olink's supply chain, a function of critical importance to Olink's success and differentiation.

08:16 EDT Guardant Health expands strategic collaboration with Merck KGaA in oncology - Guardant Health announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, to further leverage the GuardantINFORM real-world evidence platform to help accelerate development efforts for Merck KGaA, Darmstadt, Germany's precision oncology pipeline. The expanded strategic collaboration will focus on therapy development for core cancer indications with significant unmet need. "Expanding our collaboration with Merck KGaA, Darmstadt, Germany, represents a great opportunity to help accelerate the development of their pipeline of potentially transformative cancer medicines," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "We are excited to see how further leveraging the GuardantINFORM real-world evidence platform can help them bring much-needed cancer therapies to patients more quickly." Under the expanded collaboration, Merck KGaA, Darmstadt, Germany, will work closely with data scientists at Guardant Health on a variety of therapy development initiatives that utilize the genomics and clinical information accessible through the GuardantINFORM platform.

08:14 EDT Denali Therapeutics announces new interim data from Phase 1/2 study of DNL310 - Denali Therapeutics announced new interim results from a Phase 1/2 trial of DNL310 in MPS II. DNL310 is an investigational, brain-penetrant enzyme replacement therapy designed to address the cognitive, behavioral, and physical manifestations of Hunter syndrome. The data were presented at the 2022 Society for the Study of Inborn Errors of Metabolism Annual Symposium. The presentation at SSIEM included data from 27 participants enrolled in the Phase 1/2 trial with data available as of the data cut off on March 22, 2022. All but one participant has neuronopathic MPS II, and the median age was 5 years. Participants received weekly intravenous doses of DNL310 starting on day 1 of the study, with no wash-out period for those switching from idursulfase. Data from additional participants in the Phase 1/2 study continue to show rapid and sustained reduction of relevant CNS and peripheral biomarkers to normal healthy levels. Rapid normalization of cerebrospinal fluid heparan sulfate levels was observed in most patients after 4 to 6 weekly intravenous doses of DNL310. Results also continued to demonstrate normalization of lysosomal lipid biomarkers in CSF, which is consistent with improved lysosomal function. After switching from idursulfase to DNL310, a mean decline from baseline of 84% and 88% was observed for heparan sulfate and dermatan sulfate biomarkers in the urine, respectively, at week 49, suggesting DNL310 has added peripheral activity over approved enzyme replacement therapy. One-year exploratory clinical outcomes data from the Phase 1/2 study were presented. For participants with assessments at week 49, most demonstrated improvement or stabilization across all domains since entering the Phase 1/2 study. The safety profile of DNL310 with up to 85 weeks of dosing remains similar to standard of care. The most frequent treatment-emergent adverse events were infusion related reactions. IRR frequency and severity decreased with continued dosing, demonstrating tolerance to dosing with DNL310. There were no treatment withdrawals or study discontinuations due to TEAEs. The study continues without modification following recommendation by an independent data monitoring committee in April 2022.

08:13 EDT SunPower CFO Sial to voluntarily resign - In a regulatory filing, SunPower Corporation disclosed that on August 26, Manavendra Sial notified the company of his intent to voluntarily resign his employment as the executive vice president and chief financial officer of the company. "Sial's resignation is not the result of any disagreement with the company on any matter relating to the company's operations, policies, or practices, including financial matters," said the filing, which noted that Sial's last day with the company is expected to be September 14. The company has commenced a search process for a new chief financial officer and has appointed Guthrie Dundas as interim chief financial officer, effective August 29. Dundas has served as the company's vice president, project finance, since March 2020 and also as its treasurer since July 2020. Prior to March 2020, he was the owner of Ponderosa Capital Solutions, which provided advisory services on corporate and project capital formation starting in April 2019, SunPower said.

08:12 EDT R1 RCM announces partnership with EPPA - R1 RCM announced an agreement to be the exclusive provider of revenue cycle management services for Emergency Physicians Professional Association, EPPA, a physician group providing high-quality emergency medicine and urgent care across Minnesota. The partnership is expected to optimize clinical, financial, and operational performance for EPPA, while bolstering the patient experience and service for its patients. "We look forward to collaborating with EPPA to deliver a comprehensive, enterprise revenue cycle solution. This partnership will not only improve their financial performance and patient experience, but also support their long-term growth objectives while fulfilling EPPA's vision of delivering excellence in emergency and urgent care medicine," said Gary Long, executive vice president and chief commercial officer at R1.

08:09 EDT Hepion Pharmaceuticals announce initiation of Phase 2b ASCEND-NASH trial - Hepion Pharmaceuticals announced that it has screened the first subject in the ASCEND-NASH clinical trial. The trial is being conducted at up to 121 sites in seven countries, with 85 of the sites located within the U.S. ASCEND-NASH is a Phase 2b, randomized, multi-center, double-blinded study to evaluate the safety and efficacy of rencofilstat in 336 subjects dosed for 12 months. Subjects included in the trial will be either F2 or F3 biopsy-confirmed, with enrollment of F3 subjects of at least 60%, to focus on NASH subjects with more advanced fibrosis. Endpoints will evaluate improvements in both fibrosis and steatosis, with the overall study primary endpoint being an improvement of fibrosis score by one point without a worsening of steatosis, or an improvement of steatosis without worsening of fibrosis. "Initiation of screening in our Phase 2b ASCEND-NASH clinical trial represents a significant step forward for our company," stated Robert Foster, PharmD, PhD, Hepion's Chief Executive Officer. "For quite some time, our team has been busy setting the stage for this major clinical trial. Our efforts have focussed on ongoing optimization of drug manufacturing and product formulation; packaging; qualification of trial sites; and engagement with contract research organizations and regulatory agencies around the world. While these activities are time- and resource-intensive, it is gratifying to now see them culminate in the initiation of subject screening." Dr. Foster continued, "Finally, our goal is to create an ecosystem built around rencofilstat as the core asset. To that end, we are utilizing our proprietary AI-POWR tools to explore ways to create companion diagnostics to help identify which subjects may best respond to rencofilstat. We anticipate this approach of bundling rencofilstat with companion diagnostics will be advantageous when conducting future clinical trials, and developing a commercial strategy."

08:08 EDT Xtant closes first tranche of $9.75M private investment - Xtant Medical Holdings announced the closing of the first tranche of its previously announced private placement with a select group of accredited investors led by Stavros Vizirgianakis. The Company sold approximately 14.1 million shares of common stock and warrants to purchase approximately 3.5 million shares of common stock for an aggregate purchase price of approximately $6.75 million. The Company intends to use the net proceeds from the transaction to support working capital and other general corporate purposes. The second closing tranche is expected to occur in early October 2022 after the filing and mailing of a definitive information statement to Xtant's stockholders informing them of the receipt of stockholder approval in favor of the second tranche of the private placement under the continued listing requirements of the NYSE American and satisfaction of other customary closing conditions. At the second closing, the investors will purchase approximately 6.2 million shares of common stock and warrants to purchase approximately 1.6 million shares of common stock for an aggregate purchase price of approximately $3.0 million. The warrants will be immediately exercisable and expire on the five-year anniversary of the first closing. The gross proceeds to the Company from both tranches of the transaction are expected to be approximately $9.75 million, before deducting estimated offering expenses payable by the Company.

08:08 EDT Lightning eMotors a strategic partnership with GoBolt to make EV vans, trucks - Lightning eMotors it has entered into a strategic partnership with GoBolt - a technology-led, customer-centric sustainable logistics provider - to manufacture 170 all-electric cargo vans and box trucks over the next 12 months. These vehicles will be deployed across the U.S. and Canada. As part of this agreement, Lightning eMotors will deliver 70 Class 3 zero-emission, all-electric cargo vans and 100 Class 5 zero-emission, all-electric box trucks. Deployment of the Class 3 vans is already underway. The fleet will feature a mix of 80kWh and 120kWh battery capacity vans with an expected range of up to 200 miles per charge. Development of the Class 5 box trucks is in progress, with deliveries targeted to begin early next year. Toronto-based GoBolt recently announced it has expanded operations into the U.S., positioning the company to reach 12.75 million additional households with a simplified, customer-centric, and sustainable approach to vertical supply chain integration.

08:05 EDT Brown-Forman sees FY23 capital expenditures $190M-$210M - The company said, "The company anticipates continued growth in fiscal 2023 despite global macroeconomic and geopolitical uncertainties. Accordingly, we reiterate our guidance and continue to expect the following in fiscal 2023: With the strength of our portfolio of brands and strong consumer demand, we expect organic net sales growth in the mid-single digit range. Considering the net effect of inflation and the removal of the EU and U.K. tariffs on American whiskey, we project reported gross margin to increase slightly. Based on the above expectations, we anticipate mid-single digit organic operating income growth. We expect our fiscal 2023 effective tax rate to be in the range of approximately 22% to 23%. Capital expenditures are planned to be in the range of $190 to $210 million."

08:04 EDT Aquestive Therapeutics receives DFA tentative approval for Libervant Buccal Film - Aquestive Therapeutics announced that the U.S. Food & Drug Administration has granted tentative approval for Libervant Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. "Tentative approval" means the FDA has concluded that Libervant has met all required quality, safety, and efficacy standards for approval but, due to an existing FDA regulatory grant of orphan drug market exclusivity for Valtoco, a diazepam nasal spray product, Libervant is not yet eligible for marketing in the United States. As a result of the FDA determination, the Agency cannot give final approval for Libervant until the expiration or inapplicability of the orphan drug market exclusivity, including, for example, by court order, a selective waiver of the orphan drug exclusivity, or a reversal of the FDA's decision and determination that Libervant is "clinically superior" to Valtoco. During the review process, the Company submitted to the FDA the results of a 2021 Aquestive sponsored randomized, open-label, two-sequence, two-period, two-treatment crossover study to evaluate the effect of food on the pharmacokinetics of Valtoco in healthy adult subjects. The results of this study indicated that, when Valtoco is administered after a high fat meal, the maximum drug concentration was reduced by 48% compared to Valtoco administered to subjects in a fasted state. The study also showed that the time to maximum drug concentration of Valtoco doubled from 2 hours to 4 hours when administered after a high fat meal. The FDA's decision concluded that the information Aquestive submitted was not sufficient to overturn the Agency's previous conclusion regarding the lack of food effect for Valtoco. Aquestive will seek to gain alignment with the Agency on a reasonable path to appropriately characterize the food effect of Valtoco including potentially conducting a comparative study as indicated by the FDA.

08:02 EDT TD Synnex, Syniti announce partnership - Syniti announced a new partnership with TD Synnex. This partnership will provide enterprises with new access to Syniti's award-winning data management solutions. The first solution available through this new partnership is Syniti Replicate, a data replication software with change data capture that enables the timely, relevant data enterprises need to make critical business decisions and support transformative experiences.

07:47 EDT Rekor Systems enters parking contract with Augusta University Health - Rekor Systems announced that it has been awarded a multiyear contract to digitize parking permitting for Augusta University Health System in Augusta, Georgia. AU Health provides comprehensive routine-to-complex care at the AU Medical Center, which houses the region's only Level 1 trauma center, as well as at Children's Hospital of Georgia, Georgia Cancer Center, historic Roosevelt Warm Springs Rehabilitation and Specialty Hospitals, Georgia War Veterans Nursing Home, and more than one hundred primary and specialty care clinics across the state. In addition to deploying Rekor's vehicle recognition technology at the AU Health campuses, the Company's joint venture parking partner ROKER, will provide an end-to-end solution for simplified parking permitting, electronic citation management and parking enforcement for AU Health. This end-to-end solution is enabled by Rekor Systems' vehicle recognition solutions and Roker's blockchain and digital permit management technology.

07:46 EDT Apollo Endosurgery announces ESG procedure featured in IFSO paper - Apollo Endosurgery announced that the endoscopic sleeve gastroplasty procedure was featured in a 2022 Top 10 Paper at the International Federation for the Surgery of Obesity and Metabolic Disorders 2022 World Congress, held August 23-27 in Miami. Dr. Brandon VanderWel, Bariatric & Metabolic Surgeon at EVIVA in Seattle, Washington, presented the paper entitled "Endoscopic Sleeve Gastroplasty Complements a Bariatric Surgery Practice". The paper is a retrospective review aimed at measuring the impact of integrating the ESG procedure into a bariatric surgery program in a community setting. Procedural volumes from 2020-2021 and clinical outcomes at 12 months were reported. Highlights include: Upon offering the ESG procedure, EVIVA received 469 new patient consults specific to ESG procedure over a two-year period; 197 patients underwent an ESG procedure and 107 patients received a laparoscopic sleeve gastrectomy. In these patients undergoing ESG, the total body weight loss at 12 months was 24% and the excess body weight loss was 75%. The rate of serious adverse events was 1%. In patients with hypertension, 45% were found to be in remission, 20% demonstrated improvement, and 35% demonstrated no change in hypertension at 12 months. In patients with diabetes, 55% were found to be in remission, 33% demonstrated improvement, and 11% demonstrated no change at 12 months.

07:44 EDT Bed Bath & Beyond down 24% after offering details on strategic plans - Shares of Bed Bath & Beyond are down $2.92, or 24%, to $9.19 in pre-market trading after the company announced a strategic and business update. Sue Gove, Director and Interim CEO, commented, "We are embracing a straight-forward, back-to-basics philosophy that focuses on better serving our customers, driving growth, and delivering business returns. In a short period of time, we have made significant changes and instituted enablers across our entire enterprise to regain our dominance as a preferred shopping destination for our customers' favorite brands and exciting products. We command a special presence in the Home and Baby markets, and we intend to fulfill our opportunity to be the category retailer of choice. We are working swiftly and diligently to strengthen our liquidity and secure our path for the future. We have taken a thorough look at our business, and today, we are announcing immediate actions aimed to increase customer engagement, drive traffic, and recapture market share. This includes changing our merchandising and inventory strategy, which will be rooted in National Brands. Additionally, we are focused on driving digital and foot traffic, as well as optimizing our store fleet. We believe these changes will have a widespread positive impact across customer experience, inventory assortment, supply chain execution and cost structure. The customer underpins our decisions, and we are committed to delivering what they want while driving growth, profitability, and financial returns."

07:42 EDT Bed Bath & Beyond confirms 'strategic potential' of buybuy BABY banner - The Strategy Committee of the Board of Directors, with the assistance of independent strategic and financial advisors, has completed a comprehensive review of the inherent value of the Company's buybuy BABY banner, which confirmed the banner's strategic potential. The Board of Directors believes that, at this time, buybuy BABY will deliver greater value for the company's shareholders as part of the Bed Bath & Beyond Inc. portfolio. The Board of Directors and management team have identified several strategies to implement impactful, organic changes to accelerate further growth and unlock the brand's full potential including building on its digital and registry platforms, addressing additional age groups and expanding products and services. The Board of Directors' Strategy Committee will continue to monitor the buybuy BABY business as it preserves optionality and future value creation.

07:41 EDT Rekor Systems announces parking contract with Augusta University Health - Rekor Systems announced that it has been awarded a multiyear contract to digitize parking permitting for Augusta University Health System in Augusta, Georgia. AU Health provides comprehensive routine-to-complex care at the AU Medical Center, which houses the region's only Level 1 trauma center, as well as at Children's Hospital of Georgia, Georgia Cancer Center, historic Roosevelt Warm Springs Rehabilitation and Specialty Hospitals, Georgia War Veterans Nursing Home, and more than one hundred primary and specialty care clinics across the state. In addition to deploying Rekor's vehicle recognition technology at the AU Health campuses, the Company's joint venture parking partner ROKER will provide an end-to-end solution for simplified parking permitting, electronic citation management and parking enforcement for AU Health. This end-to-end solution is enabled by Rekor Systems' vehicle recognition solutions and Roker's blockchain and digital permit management technology.

07:40 EDT Asante Gold announces filing of NI 43-101 technical report for Kubi Gold Project - Asante Gold Corporation announced the filing of a technical report in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects in connection with the Preliminary Economic Assessment on Asante's Kubi Gold Project located in the Ashanti region of Ghana. The technical report entitled "NI 43-101 Technical Report, Kubi Gold Project, Ghana, West Africa" dated August 29, 2022 has been prepared for Asante by dMb Management Services and Bara Consulting. The Technical Report demonstrates the economic viability of underground mining of the Kubi Main mineral deposit as defined in a prior technical report prepared by SEMS Exploration Services Ltd in December, 2014. The Technical Report includes a proposal for early underground development to allow for further exploration drilling from underground platforms. Key highlights of the Technical Report include: Underground mining which enhances the economic potential of the Kubi Project through robust cash flows and rapid payback; Measured and Indicated Mineral Resources of 1.32Mt Au at 5.48g/t and Inferred Mineral Resources of 0.67Mt Au at 5.31g/t. Early underground development to support further exploration activities: Underground exploration drilling to expand current resources; Geotechnical studies and further metallurgical test work; Process 1.55Mt Run-of-Mine @ 4.19g/t Au for 6,510kg Au; Process recovery of 92.5% recovery yielding 193,600oz Au at a recovered grade of 3.87g/t; Total project revenue over life of mine estimated at US$288 million based on a gold price of US$1,750 and payability of 85%; Capital cost - total project and sustaining capital cost of US$117.40 million; Operating cost of US$99.92 million; AISC of US$911/oz; Post tax NPV of US$30.70 million and Project IRR of 25% with a payback of peak funding in two years; Adequately funded to complete Pre-Feasibility Study and 17,000m drill program; Appreciable community and traditional authority support. Dave Anthony, President and CEO, stated: "We are pleased to submit this Technical Report which demonstrates significant potential for Kubi to be a standalone project. We believe the early underground development to support further exploration activities will upgrade and expand the resources even further. Asante thanks the Kubi technical team and principal consultants dMb Management Services Pty Ltd and BARA Consulting Pty Ltd for delivering the Technical Report."

07:39 EDT Bed Bath & Beyond realigns executive leadership team, eliminates COO role - The company has realigned its executive leadership team to reflect the strategic priorities and changes announced today. Mara Sirhal has been appointed to Executive Vice President and Brand President of Bed Bath & Beyond. In addition, Patty Wu has been promoted to Executive Vice President and Brand President of buybuy BABY. The newly created Brand President roles will be responsible for each banner's merchandising, planning and allocation, brand marketing, and stores, and will report directly to Gove. Sirhal most recently served as the company's Executive Vice President and Chief Merchandising Officer for the Bed Bath & Beyond banner. Sirhal joined the company in January 2021 as Senior Vice President and General Manager for Harmon to lead all operational aspects of this business. Sirhal's retail experience includes nearly 20 years across a variety of categories in merchandising, product development, planning, digital, inventory management, supplier diversity, and leased businesses at Macy's. Wu has served as the Senior Vice President and General Manager of buybuy BABY since joining the company in January 2021. Prior to buybuy BABY, Wu held several executive leadership positions across retail and business, including the roles of Chief Commercial Officer of Beautycounter, Chief Commercial Officer and General Manager of the Baby Division at The Honest Company, as well as senior management roles at Mattel, Inc. and Walmart. In conjunction with these changes, the company has eliminated the COO and Chief Stores Officer roles. Accordingly, John Hartmann and Gregg Melnick will be departing the company.

07:38 EDT PyroGenesis announces in-factory audit of NexGen metal powder production - PyroGenesis Canada announces that, further to its press release dated July 18th, 2022 and Outlook section of its Q2 2022 Financial Results press release, a tier one North American global aerospace company will, in September, be conducting an in-person powder production audit at PyroGenesis' metal powder production facility in Montreal, a significant step in a previously announced qualification agreement. This on-site, in-person powder production audit is part of the final phase of the qualification process which has spanned over 18 months of investigative rigor by the Client. This portion of the audit will consist mainly of a facilities and operations assessment, during which PyroGenesis' technicians and operators will demonstrate the reliability of the Company's metal powder production facility and work instruction processes. The in-person audit is formally scheduled to take place in September. The exact date will not be disclosed for confidentiality reasons. Upon successful completion of this in-person audit, the last step will include providing final powder samples to test specific mechanical and chemical properties. Once all steps are completed and testing is finished, PyroGenesis' process will be locked down and ready to receive commercial orders; no further changes will be allowed. Furthermore, the Client will certify the company's metal powders for use by the customer and its component suppliers. The formal and methodical process with this leading aerospace company is anticipated to achieve final approval towards the end of this year. Separately, as previously announced, the company continues to pursue a strategy to build and operate a metal powder manufacturing facility in Europe to address the anticipated parallel growth in the European market. Management has already initiated serious discussions with potential partners and is actively analyzing this opportunity. The Company will provide more information on this development as events develop.

07:37 EDT Bed Bath & Beyond to exit a third of its Owned Brands - Customers are expected to benefit from swift actions the company is taking in its Bed Bath & Beyond banner to rebalance its assortment and improve inventory. These include adjusting merchandise allocations to lead with customer preference and bringing back popular national brands and introducing new, emerging direct-to-consumer brands. The company is working expeditiously to increase its National Brands inventory where possible and will increase inventory penetration by 20 percentage points over the long term. Accordingly, the company will be exiting a third of its Owned Brands by discontinuing three of its nine labels (Haven, Wild Sage and Studio 3B). The breadth and depth of inventory across the company's six remaining Owned Brands (Simply Essential, Nestwell, Our Table, Squared Away, H for Happy and Everhome) will be substantially reduced to 20 percentage points, reflecting a more balanced sales to stock ratio moving forward.

07:37 EDT Bed Bath & Beyond plans 20% reduction in corporate, supply chain workforce

07:35 EDT DavidsTea signs credit agreement with Bank of Nova Scotia - DAVIDsTEA entered into an agreement with the Bank of Nova Scotia for a revolving line of credit in an amount of C$15M. The line of credit is secured by a first-ranking security in favour of the Bank. In addition, Investissement Quebec has provided a loan loss guarantee under its "Loan Loss Program," securing 50% of any loss incurred by the Bank with respect to recovery of indebtedness under the line of credit.

07:35 EDT Guardforce announces new executive leadership team - Guardforce AI announced a series of appointments to form a new management team to support the Company's accelerated growth in the robotics and information security markets. Lei Wang, who serves as Chief Executive Officer of Guardforce AI, has been appointed Chairman of the Board, and will continue to serve as Chief Executive Officer. Lin Jia has been appointed President. Yu-Heng Ma has been appointed Chief Financial Officer and Mingchang Liu has been appointed Chief Technology Officer. The Company also announced that, effective August 31, 2022, Wing Khai Yap resigned from his position as Chairman of the Board to pursue other interests. Also effective August 31, 2022, Chung Chi Ng resigned from her position as the Company's Chief Financial Officer to pursue other interests. Prior to his appointment as President, Lin Jia served as Guardforce AI's Head of Research & Development since May 2022. Yu-Heng Ma brings more than 20 years of experience in finance and accounting, including with several publicly listed companies. He previously served as Chief Financial Officer at China Grand Star Luxury Cars Investment Holdings Limited. Mingchang Liu has served as Manager of the Technical Development Department at Shenzhen GFAI Robot Technology, a wholly-owned and recently acquired subsidiary of Guardforce AI since March 2022.

07:34 EDT Daktronics expects 'volatile supply chain' to persist throughout fiscal year - CEO Reece Kurtenbach added, "We anticipate a dynamic and volatile supply chain and tight labor market to persist throughout this fiscal year. This environment constrains our capacity and efficiency even though customer demand remains strong. To adapt to this situation, we are carefully aligning orders to our capacity to best serve our customers and improve profitability. We are carefully adjusting our production schedules, inventory levels, pricing, and capital investments to increase our capacity and predictability. As we work through the near-term challenges, we continue to strategically invest in new technologies and solutions, resilient supply chains, and serving our existing customers and growing key markets. These strategies position us for long-term growth and increasing value for stakeholders, while prudently managing costs."

07:32 EDT Bed Bath & Beyond commenced closure of about 150 lower-producing stores

07:30 EDT Sequans closes 5G partnership agreement, sees Q3 revenue up at least 10% q/q - Yesterday morning, the company "announced the closing of a multi-year, strategic 5G licensing agreement with a new strategic partner. Under the terms of the agreement, the first three years' revenue is expected to be in excess of $50 million. An initial payment in excess of 25% of the license will be received within 30 days of the closing, with additional milestone payments scheduled to be received regularly over the next three years. The partner has the rights to manufacture and sell the Taurus platform exclusively in the Chinese market for negotiated royalty payments on its future chipset sales... The following statement is based on management's current assumptions and expectations and assumes no increase in the severity or duration of the COVID-19 pandemic, China's pandemic lockdowns and supply chain disruptions on the timing of product shipments and project advancement. Management is targeting sequential revenue growth of at least 10% in the third quarter of 2022, with gross margin in excess of 65%." CEO Georges Karam also stated: ""We are delighted to announce this new 5G strategic licensing agreement for our Taurus platform, which we expect to fund the balance of its development and expand our addressable market to China, a market currently not served by Sequans. The agreement will generate licensing revenue over the first three years and royalty revenue for 20 years on the sale of partner's products based on our 5G technology. For the remainder of 2022, we expect this licensing revenue, when combined with our current expectations for the rest of our business, will enable us to target non-IFRS operating profitability for the second half of the year and non-IFRS operating break-even in 2023. We believe our Taurus technology is uniquely positioned to be a leading 5G solution fully optimized for enhanced broadband and critical IoT applications. This, combined with the flexibility of our business model, makes us an attractive potential partner to many players interested in new 5G applications and markets."

07:20 EDT Flyht Aerospace retains Satichi Consulting for corporate development services - FLYHT Aerospace Solutionsannounced that it has retained Satichi Consulting for corporate development and capital markets communications services. Pursuant to an agreement between the parties, Satichi will be responsible for, among other matters, developing and executing a comprehensive and strategically aligned investor relations program focused on: raising awareness in the financial community across Canada and enhancing visibility of the Company; coordinating investor roadshows in the United States in tandem with FNK IR LLC; and assisting in the preparation of corporate materials. Under the terms of the agreement, Satichi will receive C$5,000 per month from FLYHT with an initial term of 12 months and thereafter on a month-to-month basis. Either party may terminate the agreement by providing 60 days written notice. Subject to TSX approval, under this agreement, Satichi will be granted 120,000 stock options at an exercise price per share equal to the Company's market price of the shares on the date of issuance and subject to the pricing rules of the TSX Venture Exchange in relation to options. The options will be subject to the vesting of 30,000 per quarter over the calendar year and shall be exercisable until August 10, 2026. The options are subject to the terms of the Company's stock option plan and the stock option agreement and will be subject to regulatory hold periods.

07:17 EDT Biohaven Pharma's Nurtec shows barbiturate use reduction in migraine patients - Biohaven Pharmaceutical announced findings pertaining to the benefit of Nurtec ODT - rimegepant - in decreasing the burden of butalbital use among migraine patients in real world clinical practice. Neurologist Katherine Standley, Medical Director, Biohaven, commented "Butalbital has a high risk of leading to medication overuse headaches, and has led to the American Academy of Neurology and the American Headache Society to recommend avoiding its use as a first line agent in the treatment of headaches." Among the 24,359 with migraine who used butalbital prior to initiating treatment with Nurtec ODT, approximately 49% had no butalbital prescription fills in the 6 months following initiation. The overall butalbital discontinuation rate after Nurtec ODT initiation was 48.7%. Overall, mean monthly butalbital prescription fills decreased by 31.9% and mean milligrams dispensed reduced by 26.2%. Nurtec ODT was approved by the FDA for the acute treatment of migraine in February 2020 and for the preventive treatment of episodic migraine in May 2021.

07:13 EDT OTC Markets Group welcomes Montage Gold to OTCQX - OTC Markets Group announced Montage Gold, a gold exploration and development company focused in Cote d'Ivoire, has qualified to trade on the OTCQX Best Market. Montage Gold Corp. upgraded to OTCQX from the Pink market.

07:11 EDT DoubleDown to donate $10,000 to ASPCA - DoubleDown Interactive announced a $10,000 donation to the ASPCA in support of its mission to provide effective means for the prevention of cruelty to animals throughout the United States.

07:09 EDT BioCardia says DSMB recommends Phase III CardiAMP trial continue as designed - BioCardia announces that the independent Data Safety Monitoring Board has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP Cell Therapy Heart Failure Trial, for which FDA granted Breakthrough Designation earlier this year. The DSMB based their review on available data for all participating patients enrolled, including 101 patients at or past the 12-month primary endpoint. The DSMB performed a risk-benefit assessment, indicated no significant safety concerns, and recommended that the study continue as designed. The DSMB also recommended that BioCardia consider implementing an adaptive statistical analysis plan which could enable an early readout for study treatment efficacy. Patient visit data was available for 93% or more of all patients at all follow-up endpoints. Blinded results across all patients are showing a survival rate at one year follow-up that is greater than that observed in recent similar large pivotal trials in patients with heart failure with reduced ejection fraction.1,2 For study subjects followed-up to date through the key visit dates in this study, mean health outcomes across both treated and control patients including six minute walk distance test, patient status assessed by New York Heart Association class, quality of life measured using the Minnesota Living with Heart Failure questionnaire, and heart function assessment such as left ventricular ejection fraction, are demonstrating favorable trends for meaningful clinical improvement. Whether the difference in outcomes between the two patient study groups enrolled and randomized into the current trial exists won't be known until the data is unblinded and analyzed formally in accordance with the prespecified statistical analysis plan. The ongoing multi-center, double-blind, randomized, controlled pivotal CardiAMP Cell Therapy Trial for Heart Failure is expected to enroll 260 patients at up to 40 centers in the U.S. and Canada. The trial's primary endpoint is an outcomes composite score based on a three-tiered Finkelstein-Schoenfeld hierarchical analysis, an established outcomes design that has been used in other leading heart failure programs. The FS procedure is a ranked analysis that compares occurrence of cardiovascular and other health-related events, along with functional capacity measures, through one year in patients receiving the study treatment to patients in the control arm who don't receive the study treatment. Data submitted to the DSMB for review provided the group with visibility into the risks and benefits of the trial at its primary endpoint.

07:08 EDT Barnes & Noble Education sees FY23 adjusted EBITDA $30M-$40M - The company said, "For fiscal year 2023, the Company expects consolidated non-GAAP Adjusted EBITDA to be between $30 million to $40 million. The Company expects significant improvement in its Retail business being driven by new First Day Complete implementations, growth within its general merchandise business and new business wins. The challenges within its wholesale business, including constrained used book inventory and higher inflationary pressures on wages and freight, are expected to persist. DSS non-GAAP Adjusted EBITDA is expected to be near fiscal year 2022 levels as revenue growth is offset by investments in product enhancements."

07:07 EDT Sealed Air extends contract of CEO Ted Doheny through December 31, 2027 - SEE announced its Board of Directors has extended the contract of SEE President and CEO Ted Doheny through December 31, 2027. "SEE is on a journey to become a world-class, digitally driven company automating sustainable packaging solutions. Over the past five years, Ted has architected our purpose-driven transformation and energized our growth during one of the most challenging times in the company's history. We are confident that Ted is the right leader to continue to successfully advance our long-term strategy and accomplish our vision," said Henry Keizer, SEE's Chairman of the Board.

07:06 EDT DraftKings slated to launch mobile sportsbook in Kansas on September 1 - DraftKings announced plans to launch its online sportsbook in Kansas tomorrow on September 1, 2022, subject to receipt of regulatory approvals. Upon launch, Kansas would become the 18th U.S. state in which DraftKings offers its online sportsbook and adds to DraftKings' total sports betting footprint that spans 19 U.S. states and Ontario, Canada, inclusive of retail-only jurisdictions. DraftKings, as the contracting counterparty of BHCMC, manager of Boot Hill Casino & Resort, will, subject to receipt of regulatory approvals, offer eligible customers in Kansas the opportunity to place legal and regulated bets across professional and collegiate sporting events and have more "skin in the game" with access to various DraftKings offerings. "We're thrilled to have the opportunity to deliver our award-wining products to Kansas sports fans for the 2022 NFL and college football seasons," said Matt Kalish, DraftKings Co-Founder and President, DraftKings North America. "It's an especially exhilarating time of year, and we are excited for eligible Kansans to be able to get in on all the action through DraftKings' seamless and responsible sports betting experience."

07:05 EDT Medtronic announces partnership with BioIntelliSense, terms not disclosed - Medtronic announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S. hospital and 30-day post-acute hospital to home distribution rights of the BioButton multi-parameter wearable for continuous, connected monitoring. The partnership enables the Medtronic Patient Monitoring business to offer access to a medical grade device that provides continuous vital sign measurements of general care patients in-hospital as well as post-discharge. This supports the simplification of care delivery through workflow automation, enabling proactive clinical intervention, and helping to address the implications of staffing shortages. Terms of the deal were not disclosed.

07:05 EDT BioCryst announces FDA grants orphan drug designation for BCX9250 - BioCryst Pharmaceuticals announced the U.S. Food and Drug Administration, FDA, has granted orphan drug designation for BCX9250 for the treatment of fibrodysplasia ossificans progressiva, FOP. "We appreciate the FDA's decision to grant orphan drug designation to BCX9250 as we work toward our goal of bringing this important oral investigational therapy to FOP patients. The benefits available to us through this designation - and the designations we previously received from the FDA and the EMA - have the potential to advance our ALK-2 inhibitor program as efficiently as possible as we move towards beginning trials in FOP patients next year," said Dr. Helen Thackray, chief research and development officer of BioCryst. BioCryst will present three posters featuring data from non-clinical studies and first-in-human Phase 1 safety, tolerability and pharmacokinetics study in healthy subjects from the BCX9250 program at the American Society for Bone and Mineral Research Annual Meeting.

07:02 EDT Nuwellis announces new clinical data on Aquadex FlexFlow System - Nuwellis announced the publication of key clinical data supporting the use of ultrafiltration with the Aquadex FlexFlow System in high-risk postoperative coronary artery bypass grafting, CABG, patients in the Journal of Cardiac Surgery. The study, "The Use of Simple Ultrafiltration Technology as a Fluid Management Strategy for High-Risk Coronary Artery Bypass Grafting Surgery," is a real-world retrospective review of postoperative isolated CABG patients who were treated in the Division of Cardiothoracic Surgery at Baylor Scott & White Health in Temple, Texas between January 1, 2020 and July 31, 2021. A total of 254 CABG procedures were performed during this period, and ultrafiltration was used in 17 patients. Despite an elevated mean Society of Thoracic Surgeons mortality score of 5.7%, the 30-day survival rate of patients treated with ultrafiltration was 100%. "We are pleased with the results of this first-of-its-kind study highlighting the benefits of Aquadex therapy for high-risk CABG patients," said Nestor Jaramillo, Jr., President and CEO of Nuwellis. "The Aquadex System offers a significant opportunity to the medical community to improve clinical outcomes. In 2019, we made the decision to expand our strategic focus to include the use of Aquadex in critical care (cardiac surgery) and pediatric settings. Today, critical care represents approximately 40% of our total revenue, confirming the execution of the strategy and the clinical value of the Aquadex System in this patient segment."

06:52 EDT Bed Bath & Beyond down 16% in pre-market at $10.23 after filing to offer stock

06:49 EDT Express sees Q3 comparable sales down year-over-year in mid-single digits - Expects Q3 bross margin rate to decrease approximately 350 basis points.

06:33 EDT BitNile's Gresham Worldwide booked new orders exceeding $10M in Q2 - BitNile Holdings announces that its global defense business, Gresham Worldwide, increased booked orders for new business from $8.1M in the first quarter ended March 31, 2022 to over $10M in the second quarter ended June 30, 2022, an increase of over 23%. Gresham Worldwide's operating companies secured significant new orders in the second quarter as demand for the Gresham's solutions increased as a result of active military budgets and recent supply chain efficiencies for Gresham. Gresham believes the continued impact of the pandemic, geopolitical military tensions, and inflation concerns have prompted its customers to increase order volume to hedge purchase prices against anticipated increases and ensure the availability of critical supply chain components that have recently hindered productivity. In Q2 2022, Gresham's operating companies continued to grow globally. Gresham expects ongoing global conflicts and continued concerns regarding industry supply chains to sustain its bookings momentum through the end of 2022 and into 2023.

06:26 EDT Radware selected by telecom provider Odine for global cloud protection - Radware was selected by Odine to provide Cloud DDoS Protection Services as part of the system integrator's global network infrastructure modernization project. Odine offers virtualized end-to-end communication solutions to Tier-1 telecom providers. Faced with defending their systems against DDoS attacks, Odine deployed Radware's Cloud DDoS Protection Service to protect 14 of its networks and two of its data centers. Radware closed the deal in conjunction with its partner, INAP.

06:06 EDT Donaldson sees FY23 CapEx $115M-$135M - FY23 free cash flow conversion is projected to be between 110%-125%. Donaldson expects to repurchase approximately 2% of its outstanding shares during fiscal 2023.

06:04 EDT Vivani Medical commences trading under new ticker symbol - Vivani Medical, formerly Second Sight Medical, announced that trading of the company's common stock on The Nasdaq Capital Market under the symbol "VANI" will commence August 31. Vivani is the combination of Nano Precision Medical and Second Sight Medical Products. Closing of the merger was completed and announced yesterday, August 30.

06:03 EDT Toyota announces additional $2.5B investment in TBMNC facility - Toyota announced an additional investment of $2.5B in its newest North American facility, Toyota Battery Manufacturing, North Carolina, or TBMNC. This investment adds capacity to support battery electric vehicle, or BEV, battery production and adds 350 jobs, bringing the total employment to approximately 2,100. Scheduled to begin production in 2025, the facility will produce batteries for hybrid electric vehicles, or HEV, and BEVs.

05:29 EDT Sorrento Therapeutics announces Scilex granted fast track designation for SP-103 - Scilex announced that FDA has granted fast track designation for its investigational drug and device product candidate, SP-103. Scilex is a nearly 100% majority-owned subsidiary of Sorrento Therapeutics.

05:18 EDT NetEase acquires Quantic Dream, terms undisclosed - NetEase announced that its games division, NetEase Games, has acquired Quantic Dream S.A., an independent video game developers in the world. Quantic Dream, led by David Cage and Guillaume de Fondaumiere, will become NetEase Games' first studio in Europe, representing an important step in fulfilling NetEase's vision to support innovation and game development around the globe. Quantic Dream will continue to operate independently, focusing on creating and publishing its video games on all platforms, as well as supporting and publishing third-party developed titles, while at the same time leveraging NetEase's significant game development capabilities. Quantic Dream is a studio that was established 25 years ago in Paris, France. It is the creator of games such as Heavy Rain, Beyond: Two Souls and Detroit: Become Human. The studio announced at The Game Awards 2021 that it is working in collaboration with Lucasfilm Games on the new action-adventure game, Star Wars Eclipse.

05:11 EDT Tencent Music announces partnership with Billboard - Tencent Music announced a new partnership with Billboard. The partnership leverages TME's technologies and Chinese music industry insights with Billboard's global brand authority, drawing on both domestic and international markets to promote Chinese music around the world. The two parties will launch the "Chinese Music Gravity Project," an initiative dedicated to championing Chinese music across an international audience. Under the partnership, TME and Billboard will combine their expertise to highlight China's music industry and share Billboard's global content to TME's channels. This will include TME's platforms - QQ Music, Kugou Music, Kuwo Music, and WeSing. All will feature Billboard's content, authoritative charts, global music news coverage, and expert recommendations.